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Duke Clinical Research Institute, Durham, NC, USAThe last decade has seen a significant decrease in the overall
length of stay following percutaneous intervention (PCI) and is
the result of technological, pharmacological, and procedural
innovations against a background of evolving payer expecta-
tions. Same-day discharge (SDD) in eligible patients undergoing
uncomplicatedPCI is thenatural culminationof theseadvances,
with the potential to reduce resource utilization while
increasing patient satisfaction if executed properly. Although
the safety and feasibility of same day discharge among patients
undergoing transradial PCI has been well established in North
America, the application of such a strategy in a more resource-
constrained setting such as India hadnot yet beendocumented.
In this issue of the Indian Heart Journal, Singh et al present
their institution's experience with same day discharge among
patients undergoing elective transradial PCI. The investigators
screened 710 patients, of which 61 were eligible based on pre-
specified SDD criteria; the main reason for exclusion was prox-
imity to the PCI center. Among initially eligible patients, five
were later excluded due to peri- and post-procedural compli-
cations (two underwent transfemoral access, two developed
intraprocedural stent thrombosis, and one developed post-
procedure chest pain). Of the remaining 56 patients (91.8%)
whoweredischarged the sameday as theprocedure, therewere
no ischemic or bleeding complicationswithin the first 24 h after
discharge. One patient in the SDD group developed an anterior
wall myocardial infarction three days post-procedure and un-
derwent successful fibrinolysis. Likewise, there were no
ischemic or bleeding complications in a control group of 56 pa-
tientsundergoingovernightmonitoringduring thesameperiod.
These data raise important questions about the feasibility
of adopting same-day discharge as a standard approach in
patients undergoing PCI. At the heart of most successful SDD
programs is appropriate patient selection. The authors of this
study are to be commended for carefully selecting suitable* Corresponding author. 2400 Pratt Street, Durham, NC 27705, USA.
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that experienced complications. Patient eligibility criteria can
generally be divided into pre-procedural factors, procedural/
angiographic factors, and post-procedural factors (Fig. 1).
Appropriately, this study only considered patients undergoing
elective PCI with a left ventricular ejection fraction >30%,
serum creatinine <1.5 mg/dl, and close proximity (<50 km) to
the PCI center. Patients with acute coronary syndrome (ACS)
were excluded from consideration for SDD. Although some
previous studies, including the EASY Trial,1 have demon-
strated successful SDD in the ACS population, most protocols
have excluded these patients, and it is important to do so
while refining a protocol and building institutional expertise
with SDD. An additional sine qua non for a same day discharge
protocol is to ensure that patients have the appropriate social
support at home and the ability seekmedical attention rapidly
in case of life-threatening adverse events.
In the study by Singh, only patients with successful PCI
without any vascular complications were eligible for possible
SDD. It shouldbenoted that a significantproportionof patients
had complicated lesions, including ACC/AHA type C lesions
(21.4%) and chronic total occlusions (3.6%) but did not have an
increased complication rate. Patientsundergoing PCI requiring
glycoprotein IIb/IIIa (GPI) administrationwere also included in
this analysis; many operators feel that patients receiving a
bolus of GPI during the PCImay be eligible for SDD, but patients
requiring GPI infusion warrant overnight observation in order
to complete the IV regimen. Other procedural criteria not
formally listed in this analysis that may favor overnight
monitoring include unprotected left main PCI or atherectomy.
Finally, patients had to demonstrate no post-procedural chest
pain or EKG changes and successful completion of 100mwalk.
Although clear plans for dual-antiplatelet therapy were
communicatedwith all patients,most programsmandate thatreserved.
Fig. 1 e Sample same day discharge pathway.
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ensure no additional barriers to compliance.
Although none of the 56 patients discharged successfully
on the day of their procedure developed complications within
the first 24 h following discharge, two initially eligible patients
had intra-procedure stent thrombosis and another patients
developed presumed late stent thrombosis 3 days post-PCI.
This is in contrast to previously published rates of early
stent thrombosis of <1%. Although this is a small sample and
may be an outlying phenomenon, this rate of stent thrombosis
is concerning, and if persistent, would significantly limit the
applicability of a SDD program. Possible explanations may
include operator error or the specific antithrombotic regimen.
In this protocol, patients were pretreated with 150 mg clopi-
dogrel and 150 mg aspirin and were given 5000 units of
unfractionated heparin monotherapy for the procedure
without routine use of bivalirudin or GPI. This is contrast to
other protocols in which patients are pretreated with 324 mg
aspirin and 300e600 mg clopidogrel or a more potent P2Y12
inhibitor (prasugrel, ticagrelor) prior to PCI or a bolus of GPI if
not adequately pretreated. This should be explored further.
The other critical aspect of the successful SDD program is
to ensure a clear plan in the setting of post-proceduralcomplications once the patient is discharged. Patients should
be provided clear, written instructions with a single point of
contact should they experience an ischemic or bleeding
complication. In this study, the authors note that patients
were “instructed to contact the general practitioner, their
referring cardiologist, the interventionalist, or the nearest
emergency department” in the setting of complications. A
more robust strategy would have been to include one phone
number on the discharge instructions to a medical point of
contact (physician or trained nurse personnel) that would
allow appropriate triage. Moreover, successful SDD programs
have a process to contact all discharged patients the day
following PCI to review vascular access management, medi-
cation adherence, and secondary prevention.
Although this study is presented as a safety study, the
small number of patients and the overall event rates preclude
drawing a meaningful contrast between the two strategies.
However, there are numerous observational and randomized
studies in the literature that have shown the safety of SDD
among various patient populations.2,3 This study, therefore,
should be more appropriately viewed as a feasibility study to
demonstrate the practicality of a protocol to discharge pa-
tients safely on the day of their procedure. In addition, the
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 9 0e9 292authors should use their report to refine their SDD protocol
and strive to achieve the results reported in larger series.
It is important to note that this analysis was limited to pa-
tients undergoing PCI via transradial access, but SDD has been
achieved successfully among patients undergoing PCI via
transfemoral access as well. The EPOS Study4 is the largest
randomized controlled trial comparing SDD to overnight
monitoring among patients undergoing transfemoral access
and demonstrated only 3/800 (0.4%) cases of access site com-
plications. In an analysis of SDD in the United States using the
American College of Cardiology's CathPCI Registry, >96% of
patients discharged on the day of their procedure underwent
transfemoral access.5 However, the main benefit of transradial
access appears to be the robust reductions in bleeding and
vascular access complications, described most notably in the
RIVAL (RadIal Versus femorAL access for coronary intervention)
Trial.6 In designing a SDD program, transradial access offers
clear advantages over transfemoral access. Although the
reduced rates of bleeding and vascular access complications are
the most notable, transradial patients also can sit up immedi-
ately post-procedure and may be able to ambulate soon
thereafter, potentially reducing the post-PCImonitoring period.
The authors brieflymention, but do not elaborate upon, the
economic implications of broad adoption of a SDD strategy,
especially in resource-constrained settings. Cost-savings for
SDD can be realized through a reduction in overall monitoring
costs as well as by freeing inpatient bed capacity and re-
sources, but only if earlydischarge isnotassociatedwith short-
term, preventable readmission. The economic impact of a SDD
strategywas evaluated in a post-hoc analysis of the EASY trial7
and found substantial cost-savings (USD $1141, or Rs. 70,900)
with SDD compared with overnight monitoring, driven pri-
marily by a reduction inmonitoring costs. In the present study,
overnight monitoring patients were admitted the day prior to
theprocedure anddischarged the day following theprocedure,
further extending their overall resource utilization. A transi-
tion to a SDD among low-risk, eligible patients may lead to
substantial cost-savings to providers and patients by signifi-
cantly reducing overall monitoring times.
As centers worldwide grapple with increasing need for their
services in the setting of limited resources, the time is ripe for
centers to take advantage of emerging technologies to design
innovative care delivery pathways to provide safe yet efficient
PCI services. The feasibility andapplicability of SDDmayvaryby
hospital practice setting and reimbursement scheme, but the
overall goal of providingmaximum value to the patient and the
care facility should be shared among all offering institutions.
The putative cost savings is likely higher in centers that observe
overnight monitoring patients in a standard inpatient bed
instead of in a specific observation area, as SDDwould free that
bed for another, potentially sicker, patient in need of dedicated
inpatient resources. In an environment where patients often
pay out-of-pocket, a safe, effective SDD strategy may offer sig-
nificant consumer value to individual patients, since they will
not be financially liable for the cost of an overnight hospitali-
zation. Moreover, previous analyses have demonstrated that
patients overwhelmingly prefer to be home the night of their
procedure, as long as it can be offered safely.8e10
This analysis reinforces the feasibility of SDD following
uncomplicated elective transradial PCI in appropriatelyselected patients in a resource-constrained environment and
will serve as an important pilot study for Indian centers as
they build and refine programs for SDD. If implemented
properly, SDD has the potential to reduce costs, free up
ancillary resources, and increase satisfaction among patients
undergoing PCI. Given the number of PCI's performed annu-
ally in India, the potential benefits from such cleverly
designed protocols may be sizeable.
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